PD-L1 expression in neuroendocrine tumors of the lung

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 108; pp. 115 - 120
• Main Authors: Tsuruoka, Kenjiro, Horinouchi, Hidehito, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Asakura, Keisuke, Nakagawa, Kazuo, Sakurai, Hiroyuki, Watanabe, Shun-ichi, Tsuta, Koji, Ohe, Yuichiro
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.06.2017
• Subjects: Adult; Aged; Aged, 80 and over; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Biomarkers, Tumor; Carcinoid; Clone E1L3N; Female; Gene Expression; Hematology, Oncology and Palliative Medicine; Humans; Immunohistochemistry; LCNEC; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Staging; Neuroendocrine; Neuroendocrine Tumors - genetics; Neuroendocrine Tumors - metabolism; Neuroendocrine Tumors - mortality; Neuroendocrine Tumors - pathology; PD-1; PD-L1; Prognosis; Pulmonary/Respiratory; Risk Factors; Small cell lung cancer; Young Adult; Immunohistochemistry; Clone E1L3N; Small cell lung cancer; Neuroendocrine; PD-L1; Carcinoid; LCNEC; PD-1; Clone E1L3 N

Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroe...